| Previous Close | 2.93 |
| Open | 2.99 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 3000 |
| Day's Range | 2.78 - 2.99 |
| 52 Week Range | 1.55 - 3.94 |
| Volume | 44,221 |
| Avg. Volume | 15,840 |
| Market Cap | 13.364M |
| Beta (3Y Monthly) | -0.80 |
| PE Ratio (TTM) | 5.76 |
| EPS (TTM) | 0.50 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.00 |
RAMAT GAN , Israel , Nov. 01, 2018 /PRNewswire/ -- TL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing ...
RAMAT GAN , Israel , July 24, 2018 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company ...
RAMAT GAN , Israel , May 29, 2018 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company ...
Stock Monitor: XTL Biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 13, 2017 / Active-Investors issued a free report on RXi Pharmaceuticals Corp. (NASDAQ: RXII ), which is readily accessible ...
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today announced that it has received notification from the NASDAQ Stock Market LLC ("NASDAQ") that the Company has regained compliance with the minimum $2.5 million stockholders' equity requirement for continued listing on The Nasdaq Capital Market. As previously disclosed, on October 17, 2017, the Company received a notice from NASDAQ stating that the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Rule") because the Company did not have a minimum stockholders' equity, as of June 30, 2017, of $2.5 million and the Company did not alternatively meet the market capitalization or income from continuing operations tests.
RAANANA, Israel , Nov. 27, 2017 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing ...